Baxter Posts $294M Third-Quarter Net Income
BAX sits 68% above its 52-week low of $15.73 on elevated volume (1.9× avg).
Summary
Baxter reported third-quarter net income of $294 million, with EPS of 57 cents and adjusted EPS of 58 cents on sales of $2.98 billion. The company guided to full-year adjusted EPS of $2.05 to $2.15 and raised its full-year 2026 outlook to reported sales growth of 4% to 5% and adjusted EPS of $2.05 to $2.15, and it declared a $0.01 quarterly dividend payable January 4, 2027. The results give a clearer read-through versus Q2's $2.96B sales and $0.56 adjusted EPS. Context matters here: the company has been actively reshaping its balance sheet, upsizing a debt tender to $600 million in August and loosening its net leverage covenant, and it installed John Rogers as permanent CFO effective October 1.
Updated with an SEC 8-K filing · What changed
Updates
· SEC 8-K — Baxter raised its full-year 2026 outlook: reported sales growth of 4% to 5% and adjusted EPS of $2.05 to $2.15, and declared a $0.01 quarterly dividend payable January 4, 2027.
At the time of this announcement, BAX was trading at $26.50 on NYSE in the Life Sciences sector, with a market capitalization of approximately $13.2B. The 52-week trading range was $15.73 to $30.00. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: Dow Jones Newswires.